tbuckley/cabot-search huggingface dataset:
Frequent somatic mutations of the ATBF1 transcription factor in human prostate cancer
Authors: Xiaodong Sun, Henry F. Frierson, Changling Li, Ceshi Chen, Qimei Ran, Kristen Otto, Brandi Cantarel, Allen Gao, John Petros, Yutaka Miura, Jonathan W. Simons, Robert L. Vessella, Jin-Tang Dong
Journal: Cancer Research (2005)

2882   Cancer is often a multistep disease resulting from the accumulation of multiple genetic alterations. Although most human malignancies arise sporadically rather than from genetic predisposition, only a rather small number of genes have been identified that are frequently mutated in sporadic cancers. The long arm of chromosome 16 is frequently deleted in many types of human cancers but the target gene of deletion has thus far not been identified (Dong JT, Cancer Metastasis Rev 20:173-93, 2002). Here we report that ATBF1, a transcription factor that negatively regulates alpha-fetoprotein and c-myb(Kaspar P, et al. J Biol Chem 274:14422-8, 1999; Ninomiya TK, et al. Hepatology 35:82-7, 2002) but transactivates the promoter activity of the p21 tumor suppressor gene( Kataoka HP, et al. Cancer Res 63:5785-92, 2003), is a strong candidate for the 16q22 tumor suppressor gene. Our deletion mapping studies narrowed the region of deletion at 16q22 to 861-Kb, which harbors the ATBF1 gene. ATBF1 mRNA was abundant in normal prostates but much less in about half of the cancer samples tested. In 24 of 66 (36%) prostate cancer cases examined, we identified 35 somatic mutations. Many of the mutations clearly impair the function of ATBF1, although the effect of others remains to be determined. In addition, loss of wild-type ATBF1 enhanced cell proliferation but gain of wild-type ATBF1 inhibited it. Hence, loss of wild-type ATBF1 through interruption of its regulation of downstream target gene(s) would be one mechanism that defines the absence of growth control in prostate cancer.
Caracterización de los frotis para análisis virológico en el Sistema Español de Vigilancia Centinela de la Gripe durante cuatro temporadas de gripe en el período 2002-2006
Authors: A Larrauri, S De Mateo, Spanish Influenza Sentinel Surveillance System
Journal: Eurosurveillance (2007)

El objetivo de este estudio era caracterizar los patrones de frotis en el Sistema Espanol de Vigilancia Centinela de la Gripe (SEVCG) y averiguar en que medida el sistema se atiene a las directrices formuladas actualmente por el Sistema Europeo de Vigilancia de la Gripe (EISS).
In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Stem-Like Cancer Cell
Authors: Kuan Hu, Feng Yin, Mengyin Yu, Chengjie Sun, Jingxu Li, Yujie Liang, Wenjun Li, Mingsheng Xie, Yuanzhi Lao, Wei Liang, Zi-gang Li
Journal: Theranostics (2017)

Inhibition of the interaction between p53 and MDM2/MDMX has attracted significant attention in anticancer therapy development.We designed a series of in-tether chiral center-induced helical stabilized peptides, among which MeR/PhR effectively reactivated p53.The activation of p53 inhibits cell proliferation and induces apoptosis in both the MCF-7 normal tumor cell line and the PA-1 pluripotent cancer cell line with only minimal cellular toxicity towards normal cells or cancer cell lines with p53 mutations.The in vivo bioactivity study of the peptide in the ovarian teratocarcinoma (PA-1) xenograft model showed a tumor growth rate inhibition of 70% with a dosage of 10 mg/kg (one injection every other day).This is the first application of a stabilized peptide modulator targeting stem-like cancer cell both in vitro and in vivo and provides references to cancer stem cell therapy.
Metabolic Effects of Diet and Exercise in Patients with Moderate to Severe CKD: A Randomized Clinical Trial
Authors: T. Alp Ikizler, Cassianne Robinson-Cohen, Charles Ellis, Samuel A.E. Headley, Katherine Tuttle, Richard J. Wood, Elizabeth Elspeth Evans, Charles M. Milch, Kelsey Anne Moody, Michael Germain, Chutatip Limkunakul, Aihua Bian, Thomas G. Stewart, Jonathan Himmelfarb
Journal: Journal of the American Society of Nephrology (2017)

CKD is steadily increasing along with obesity worldwide. Furthermore, obesity is a proinflammatory risk factor for progression of CKD and cardiovascular disease. We tested the hypothesis that implementation of caloric restriction and aerobic exercise is feasible and can improve the proinflammatory metabolic milieu in patients with moderate to severe CKD through a pilot, randomized, 2×2 factorial design trial. Of 122 participants consented, 111 were randomized to receive caloric restriction and aerobic exercise, caloric restriction alone, aerobic exercise alone, or usual care. Of those randomized, 42% were women, 25% were diabetic, and 91% were hypertensive; 104 started intervention, and 92 completed the 4-month study. Primary outcomes were a change from baseline in absolute fat mass, body weight, plasma F 2 -isoprostane concentrations, and peak oxygen uptake (VO 2 peak ). Compared with usual care, the combined intervention led to statistically significant decreases in body weight and body fat percentage. Caloric restriction alone also led to significant decreases in these measures, but aerobic exercise alone did not. The combined intervention and each independent intervention also led to significant decreases in F 2 -isoprostane and IL-6 concentrations. No intervention produced significant changes in VO 2 peak , kidney function, or urine albumin-to-creatinine ratio. In conclusion, 4-month dietary calorie restriction and aerobic exercise had significant, albeit clinically modest, benefits on body weight, fat mass, and markers of oxidative stress and inflammatory response in patients with moderate to severe CKD. These results suggest healthy lifestyle interventions as a nonpharmacologic strategy to improve markers of metabolic health in these patients.
<i>HSD3B1</i>—A Predictive Biomarker in Advanced Prostate Cancer
Authors: Andrew W. Hahn, Sumanta K. Pal, Neeraj Agarwal
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Moving Toward Evidence-Based Interventions for Trainee and Physician Wellness
Authors: Judy A. Shea, Lisa M. Bellini
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 15376: Systolic Blood Pressure Variability in Patients With ST-Elevation Myocardial Infarction Predicts the Long-Term Cardiovascular Outcomes
Authors: Moon-Seung Soh, Jin-Sun Park, Kyoung-Woo Seo, Hyoung-Mo Yang, Hong-Seok Lim, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Seung-Jea Tahk, Joon-Han Shin
Journal: Circulation (2016)

Introduction:  Elevated visit-to-visit blood pressure variability (BPV), independent of mean BP, has been associated with cardiovascular events in some diseases. The impact of visit-to-visit BPV after ST-elevation myocardial infarction (STEMI), however, has not been established.   Hypothesis:  This study aimed to investigate the prognostic impact of BPV on the patients after STEMI.   Methods:  We analyzed the data and clinical outcomes of the survivors after STEMI who underwent successful primary coronary intervention. In the estimate of BPV, BP measurements at discharge and at 1, 3, 6, 12, 24 and 36months were taken into account. The intraindividual standard deviation (SD) of systolic BP (SBP) across these measurements was calculated as index of BPV. Patients were classified into a high-BPV group and low-BPV group (the high-BPV group, SD ≥ median SD and the low-BPV group, SD    Results:  We enrolled 343 patients(58 ± 12 year-old) and mean follow-up duration was 68 ± 34 months. The intraindividual mean and median SD of SBP were 13.2 ± 7.6 and 12.3 mmHg. The MACE-free survival of the high-BPV group was significantly worse than the low-BPV group (log-rank  p  = 0.035, figure). For the high-BPV group, the relative risk of a MACE significantly increased by 57% (95% CI, 1.03-2.39,  p  = 0.038, Table).   Conclusions:  The visit-to-visit systolic BPV was associated with increased rate of adverse clinical outcomes in the patients after STEMI. Careful assessment of BP and trial to reduce BPV might be also important in the survivors after STEMI.
Elderly patients and ovarian epithelial cancer (OEC) or primary peritoneal carcinoma (PPC): A retrospective analysis.
Authors: Joan Manel Mane, Gonzalo Lopez de Argumedo, Ines Marrodan, Alberto Muñoz, Abigail Ruiz de Lobera, Eider Azkona, Eluska Iruarrizaga, Mikel Arruti, Elizabeth Condori, Aitziber Buque, Cristina Lopez Escola, Sergio Carrera, Guillermo Lopez-Vivanco
Journal: Journal of Clinical Oncology (2013)

e20718 Background: OEC frequency in elderly patients is increasing around the world and it’s expected to continue rising in the future. PPC is an entity with a similar behaviour. OEC is the most common cause of gynaecologic cancer-related death and it’s the fifth leading cause of cancer associated mortality among women; its relative risk is higher among elderly patients. In this study we try to identify clinical factors in elderly OEC and PPC patients in order to improve current medical management and to enhance clinical outcomes. Methods: From January 2007 to December 2011 a total of 53 elderly patients were included (≥65 years old). PPC: 11.3%; OEC: 88.7%. ECOG 0/1/2/3/4: 24.5/34/26.4/7.5/5.7%; 1.9% unknown. Stage at diagnosis: III (52.8%); IV (30.2%). Ca125 was increased in 79.2% of the cases; 64.2% of the patients underwent debulking surgery. The majority of patients (94.4%) received chemotherapy: monotherapy (13.2%) or polychemotherapy (86.8%). Results: Among 38 evaluable patients, partial response was observed in 45.4%, complete response in 27.2%, stable disease in 24.4% and progression in 3%; 18% of patients were retreated with the same schedule (platinum sensitivity) and 26.4% of the patients received more than one line of chemotherapy (range 2-5). Significant differences in overall survival (OS) were observed in multivariate analysis according to performance status (p=0.018). Median OS for all patients was 131 weeks. Conclusions: In our experience, results in elderly patients are comparable to those expected in younger patients. In this population, treatment options must be optimized.
Pigmented Macule — A Skin Manifestation of Invasive Breast Cancer
Authors: Takashi Oide, Tsuyoshi Mitsuishi
Journal: New England Journal of Medicine (2017)

A 62-year-old woman presented with stiffness of the left nipple. Palpation, mammography, and ultrasonography were normal. However, a 5-mm pigmented macule was noted on the left areola. Biopsy revealed invasive adenocarcinoma.
Leptospirosis en Portugal: situación epidemiológica entre 1991 y 1997
Authors: J M Falcão, P J Nogueira, C MatiasDias, Z. P. Pimenta
Journal: Eurosurveillance (1999)

El termino leptospirosis describe un grupo de enfermedades causadas por miembros del orden Spirochaetales, principalmente la especie Leptospira interrogans. La infeccion puede ser asintomatica, pero la enfermedad puede presentarse con distintos grados de gravedad y sintomatologia variada (sugiriendo a menudo una meningitis, encefalitis o un cuadro gripal). La duracion de la leptospirosis oscila entre algunos dias a varias semanas, segun la gravedad y el tratamiento. La tasa de letalidad es baja pero puede sobrepasar el 20% en pacientes que desarrollen insuficiencia hepatica y renal (enfermedad de Weil) y en las personas mayores.
Association of History of Gestational Diabetes With Long-term Cardiovascular Disease Risk in a Large Prospective Cohort of US Women
Authors: Deirdre K. Tobias, Jennifer J. Stuart, Shanshan Li, Jorge Chavarro, Eric B. Rimm, Janet Rich-Edwards, Frank B. Hu, JoAnn E. Manson, Cuilin Zhang
Journal: JAMA Internal Medicine (2017)

<h3>Importance</h3> Previous studies identify gestational diabetes (GD) as a risk factor for intermediate markers of cardiovascular disease (CVD) risk; however, few are prospective, evaluate hard CVD end points, or account for shared risk factors including body weight and lifestyle. <h3>Objective</h3> To prospectively evaluate history of GD in relation to incident CVD risk. <h3>Design, Setting, and Participants</h3> The Nurses' Health Study II (NHS II) is an observational cohort study of US female nurses established in 1989, with ongoing follow-up. Biennial questionnaires updated behavioral characteristics, health outcomes, and lifestyle factors. Multivariable Cox models estimated the hazard ratio (HR) and 95% CI for CVD risk. We included 89 479 women who reported at least 1 pregnancy and were free of CVD and cancer at baseline. Follow-up through May 31, 2015, was complete for more than 90% of eligible participants. <h3>Exposures</h3> History of GD was self-reported at baseline (1989) via questionnaire and updated every 2 years. <h3>Main Outcomes and Measures</h3> We observed 1161 incident self-reported nonfatal or fatal myocardial infarction or stroke, confirmed via medical records. <h3>Results</h3> Participants had a mean (SD) age of 34.9 (4.7) years. Adjusting for age, prepregnancy body mass index, and other covariates, GD vs no GD was associated with subsequent CVD (HR, 1.43; 95% CI, 1.12-1.81). Additional adjustment for weight gain since pregnancy and updated lifestyle factors attenuated the association (HR, 1.29; 95% CI, 1.01-1.65). Classifying GD by progression to T2D in relation to CVD risk indicated a positive association for GD with progression to T2D vs no GD or T2D (HR, 4.02; 95% CI, 1.94-8.31), and an attenuated relationship for GD only (HR, 1.30; 95% CI, 0.99-1.71). <h3>Conclusions and Relevance</h3> Gestational diabetes was positively associated with CVD later in life, although the absolute rate of CVD in this younger cohort of predominantly white women was low. This relationship is possibly mediated in part by subsequent weight gain and lack of healthy lifestyle.
TCTAP A-147 Clinical Impacts of Beta-blockers in Patients Following Acute Myocardial Infarction Without Heart Failure or Left Ventricular Dysfunction (Left Ventricular Ejection Fraction&gt;40%)
Authors: Hanbit Park, Sang Yong Om, Yong-Hoon Yoon, Minsoo Kim, Sang-Cheol Cho, Kyusup Lee, Osung Kwon, Do-Yoon Kang, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2018)
Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications
Authors: Shuyu D. Li, Meng Ma, Hui Li, Aneta Waluszko, Tatyana Sidorenko, Eric E. Schadt, David Y. Zhang, Rong Chen, Fei Ye
Journal: Genome Medicine (2017)

Next-generation sequencing (NGS) of cancer gene panels are widely applied to enable personalized cancer therapy and to identify novel oncogenic mutations.We performed targeted NGS on 932 clinical cases of non-small-cell lung cancers (NSCLCs) using the Ion AmpliSeq™ Cancer Hotspot panel v2 assay.Actionable mutations were identified in 65% of the cases with available targeted therapeutic options, including 26% of the patients with mutations in National Comprehensive Cancer Network (NCCN) guideline genes. Most notably, we discovered JAK2 p.V617F somatic mutation, a hallmark of myeloproliferative neoplasms, in 1% (9/932) of the NSCLCs. Analysis of cancer cell line pharmacogenomic data showed that a high level of JAK2 expression in a panel of NSCLC cell lines is correlated with increased sensitivity to a selective JAK2 inhibitor. Further analysis of TCGA genomic data revealed JAK2 gain or loss due to genetic alterations in NSCLC clinical samples are associated with significantly elevated or reduced PD-L1 expression, suggesting that the activating JAK2 p.V617F mutation could confer sensitivity to both JAK inhibitors and anti-PD1 immunotherapy. We also detected JAK3 germline activating mutations in 6.7% (62/932) of the patients who may benefit from anti-PD1 treatment, in light of recent findings that JAK3 mutations upregulate PD-L1 expression.Taken together, this study demonstrated the clinical utility of targeted NGS with a focused hotspot cancer gene panel in NSCLCs and identified activating mutations in JAK2 and JAK3 with clinical implications inferred through integrative analysis of cancer genetic, genomic, and pharmacogenomic data. The potential of JAK2 and JAK3 mutations as response markers for the targeted therapy against JAK kinases or anti-PD1 immunotherapy warrants further investigation.
Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262–70
Authors: Thomas Seisen, Sophia C. Kamran, Sarah C. Markt, Mark A. Preston, Quoc-Dien Trinh, Lindsay A. Frazier, Toni K. Choueiri, Neil E. Martin, Paul L. Nguyen, Clair J. Beard
Journal: European Urology (2017)
Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome
Authors: Gregory G. Schwartz, Christie M. Ballantyne, Philip J. Barter, David Kallend, Lawrence A. Leiter, Eran Leitersdorf, John J. V. McMurray, Stephen J. Nicholls, Anders G. Olsson, Prediman K. Shah, Jean-Claude Tardif, John Kittelson
Journal: JAMA Cardiology (2017)

It is uncertain whether lipoprotein(a) [Lp(a)], which is associated with incident cardiovascular disease, is an independent risk factor for recurrent cardiovascular events after acute coronary syndrome (ACS).To determine the association of Lp(a) concentration measured after ACS with the subsequent risk of ischemic cardiovascular events.This nested case-cohort analysis was performed as an ad hoc analysis of the dal-Outcomes randomized clinical trial. This trial compared dalcetrapib, the cholesteryl ester transfer protein inhibitor, with placebo in patients with recent ACS and was performed between April 2008 and September 2012 at 935 sites in 27 countries. There were 969 case patients who experienced a primary cardiovascular outcome, and there were 3170 control patients who were event free at the time of a case event and had the same type of index ACS (unstable angina or myocardial infarction) as that of the respective case patients. Concentration of Lp(a) was measured by immunoturbidimetric assay. Data analysis for this present study was conducted from June 8, 2016, to April 21, 2017.Patients were randomly assigned to receive treatment with dalcetrapib, 600 mg daily, or matching placebo, beginning 4 to 12 weeks after ACS.Death due to coronary heart disease, a major nonfatal coronary event (myocardial infarction, hospitalization for unstable angina, or resuscitated cardiac arrest), or fatal or nonfatal ischemic stroke.The mean (SD) age was 63 (10) years for the 969 case patients and 60 (9) years for the 3170 control patients, and both cohorts were composed of predominantly male (770 case patients [79%] and 2558 control patients [81%]; P = .40) and white patients (858 case patients [89%] and 2825 control patients [89%]; P = .62). At baseline, the median (interquartile range) Lp(a) level was 12.3 (4.7-50.9) mg/dL. There was broad application of evidence-based secondary prevention strategies after ACS, including use of statins in 4030 patients (97%). The cumulative distribution of baseline Lp(a) levels did not differ between cases and controls at P = .16. Case-cohort regression analysis showed no association of baseline Lp(a) level with risk of cardiovascular events. For a doubling of Lp(a) concentration, the hazard ratio (case to control) was 1.01 (95% CI, 0.96-1.06; P = .66) after adjustment for 16 baseline variables, including assigned study treatment.For patients with recent ACS who are treated with statins, Lp(a) concentration was not associated with adverse cardiovascular outcomes. These findings call into question whether treatment specifically targeted to reduce Lp(a) levels would thereby lower the risk for ischemic cardiovascular events after ACS.clinicaltrials.gov Identifier: NCT00658515.
Surto de Escherichia coli O157 na Suécia
Authors: T Ziese, Y Anderson, B de Jong, S Löfdahl, M Ramberg
Journal: Eurosurveillance (1996)

A infeccao por Escherichia coli pode apresentar-se de diferentes formas, incluindo diarreia moderada, colite hemorragica grave, e o sindrome hemolitico-uremico (SHU). Entre 2% a 21% dos casos tem sido observado o desenvolvimento do SHU, cuja taxa de letalidade e de 3% a 7% (1). A E. coli O157 pode ser isolada das fezes. O diagnostico de SHU e clinico, e pode ser confirmado pelo isolamento do organismo ou pela identificacao dos anticorpos para os lipopolissacarideos da E. coli O157 no sangue. Em anos recentes, varios surtos de infeccao por E. coli O157, ocorreram no Reino Unido, Canada, e Estados Unidos.